Product Information

Description

Product details

VETMEDIN®-CA1 (pimobendan) Chewable Tablets for Dogs are indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease.

Recommended for dogs diagnosed with Stage B2 preclinical MMVD, VETMEDIN®-CA1 (pimobendan) can be used for the delay of onset of congestive heart failure.
May prolong the number of symptom-free days in dogs.
VETMEDIN®-CA1 helps dogs continue to engage in the daily activities they enjoy.
Available as a beef-flavored, chewable tablet in 2 convenient dosing sizes (1.25 mg and 5 mg).
Meets FDA standards of product safety, stability, and strength

VETMEDIN®-CA1 (pimobendan) chewable tablets is conditionally approved for the treatment of dogs with myxomatous mitral valve disease (MMVD) in the pre-clinical stage B2 (asymptomatic with a murmur/abnormal heart sounds and evidence of increased heart size) to delay onset of clinical signs of heart failure. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-556 (please see full prescribing information).

Given every 12 hours, the unique dual action of VETMEDIN®-CA1 dilates the blood vessels carrying blood to and from the heart—reducing the overall load on the heart—while simultaneously improving the ability of the heart muscle to contract.

The active ingredient in VETMEDIN®-CA1 (pimobendan) helps the heart muscle to contract (pump) more effectively and it dilates blood vessels which reduces the amount of force with which the heart needs to pump blood.

Your veterinarian has prescribed VETMEDIN®-CA1 (pimobendan) because your dog has been diagnosed with myxomatous mitral valve disease (MMVD) at a stage classified as B2 (asymptomatic with a murmur and evidence of significant heart size increase). Although your dog may not have any visible signs of heart disease, VETMEDIN®-CA1 can be used to delay the progression of MMVD to heart failure.

Product sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer.

For

Dogs

Active ingredient(s)

Pimobendan

Inactive ingredients

Complete inactive ingredients list not provided by manufacturer.

Brand name

Vetmedin-CA1

Drug class

Inodilator

Product flavoring

Vetmedin-CA1 Chewable Tablets for Dogs are “beef” flavored.

*Contains pork (does not contain actual beef or chicken)

Manufacturer

Boehringer Ingelheim Animal Health USA

Product strength & size

Vetmedin-CA1 Chewable Tablets may be available in multiple strengths and/or sizes. Please ensure the selected product is appropriate for your pet, as recommended by your veterinarian.

For current availability, please refer to the product selection above.

Usage

*For complete product information, please review the full prescribing information in the manufacturer package insert.

Vetmedin-CA1 Chewable Tablets should be given orally as directed by your veterinarian. Please consult your veterinarian before making any changes or discontinuing the prescribed dosing schedule.

It is important to be consistent with how the medication is given (e.g., timing, with or without food) for every dose.

Manufacturer Dosage and Administration:

VETMEDIN®-CA1 (pimobendan) Chewable Tablets should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets.

The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening).

The tablets are scored, and the calculated dosage should be provided to the nearest half-tablet increment.

Missed doses

Administer the dose as soon as possible. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not give more medication than prescribed or two doses at once.

Storage

Store in a cool, dry place at a controlled room temperature (68 to 77°F, excursions permitted between 59 and 86°F). Keep in a tight, light-resistant container and out of the reach of children and pets. Store away from heat and direct sunlight. Do not store in the bathroom, near the kitchen sink, or in damp places. The medicine may break down if exposed to heat or moisture.

Side effects

The most common side effects seen in dogs with Stage B2 MMVD while taking VETMEDIN-CA1 Chewable Tablets are cough, vomiting, diarrhea, lethargy (lack of energy), and localized pain (such as in the neck or legs).

Contact your veterinarian immediately if your pet has difficulty breathing, collapses or loses consciousness, has a seizure, or appears to be bloated/have increased belly fluid.

Notify your veterinarian if your pet experiences any of the effects described above, or if you notice any other side effects that are persistent or troublesome.

If you notice anything unusual, please consult your veterinarian.

Precautions

*For complete product information including warnings and precautions, please refer to the manufacturer package insert.

For oral use in dogs with diagnosed with Stage B2 myxomatous mitral valve disease (MMVD) only- not for use in humans. Keep this and all medications in a secure location out of reach of children and animals to prevent accidental ingestion or overdose. Consult a physician in case of accidental ingestion by humans.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use VETMEDIN®-CA1 (pimobendan) Chewable Tablets other than as directed in labeling.

Do not administer VETMEDIN®-CA1 (pimobendan) Chewable Tablets in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.

Do not administer VETMEDIN-CA1 to dogs with Stage A or B1 preclinical myxomatous mitral valve disease (MMDV) due to the risk of cardiac pathology associated with exaggerated hemodynamic responses to VETMEDIN-CA1.

The safety of VETMEDIN®-CA1 has not been established in dogs with asymptomatic heart disease caused by etiologies other than MMVD. The safe use of VETMEDIN®-CA1 has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, or in breeding, pregnant, or lactating dogs.

Do not administer to animals with a known history or suspected allergy/hypersensitivity to this medication or any of its ingredients. Allergic reactions to medications may occur. Be sure to inform Vetsource and your veterinarian if your pet has any known drug sensitivities or allergies.

If your pet displays symptoms of an allergic reaction, discontinue therapy and call your veterinarian immediately or seek emergency veterinary attention. Symptoms may include (but are not limited to): swollen lips, tongue, face, or airways; difficulty breathing; agitation; profuse salivation; and widespread hives or itching.

Drug and food interactions

The following drugs* may have potential interactions with this medication: beta blockers (e.g., atenolol, sotalol), calcium channel blockers (e.g., amlodipine, diltiazem), and sildenafil.

*NOTE: this may not be a comprehensive list. Contact your veterinarian if your pet experiences any unusual reactions when different medications are given together.

Please ensure your veterinarian is aware of all medications and supplements that your pet is currently receiving. Your veterinarian may prescribe multiple medications, even if a potential drug interaction may occur. In these instances, your veterinarian may adjust the dosages or monitor your pet more closely.

Adverse reactions

If you are concerned that your pet has experienced an adverse reaction to this medication, please contact the manufacturer Boehringer Ingelheim Animal Health USA at 1-888-637-4251 or Vetsource Pet Owner Care at 877-738-4443.

Overdose

If you have any reason to suspect an overdose, call your doctor/veterinarian or the appropriate poison control resource immediately.

For humans:

The national toll-free Poison Help line, 1-800-222-1222, will connect you to your local poison center in case of emergency. This service is available nationwide and in most U.S. territories.

For animals:

The ASPCA Animal Poison Control Center is available 24 hours a day, 365 days a year at 888-426-4435.

Pet Poison Helpline® also provides a 24/7 animal poison control service at 855-764-7661.

*Please note: this information is for third-party services and is provided for convenience in case of potential poison-related emergencies. There may be consultation fee for these services.

Disclaimer

The content provided on this page is NOT medical advice.

All content, including the images and product description above, is intended for general informational purposes only and should not be considered a substitute for professional veterinary consultation, diagnosis, or treatment.

Consult your veterinarian for complete information about this product and how it fits into your pet's individual treatment plan.

Last revised: 8/01/2025

Description
Product details
VETMEDIN®-CA1 (pimobendan) Chewable Tablets for Dogs are indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease.
- Recommended for dogs diagnosed with Stage B2 preclinical MMVD, VETMEDIN®-CA1 (pimobendan) can be used for the delay of onset of congestive heart failure.
- May prolong the number of symptom-free days in dogs.
- VETMEDIN®-CA1 helps dogs continue to engage in the daily activities they enjoy.
- Available as a beef-flavored, chewable tablet in 2 convenient dosing sizes (1.25 mg and 5 mg).
- Meets FDA standards of product safety, stability, and strength
VETMEDIN®-CA1 (pimobendan) chewable tablets is conditionally approved for the treatment of dogs with myxomatous mitral valve disease (MMVD) in the pre-clinical stage B2 (asymptomatic with a murmur/abnormal heart sounds and evidence of increased heart size) to delay onset of clinical signs of heart failure. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-556 (please see full prescribing information).

Given every 12 hours, the unique dual action of VETMEDIN®-CA1 dilates the blood vessels carrying blood to and from the heart—reducing the overall load on the heart—while simultaneously improving the ability of the heart muscle to contract.

The active ingredient in VETMEDIN®-CA1 (pimobendan) helps the heart muscle to contract (pump) more effectively and it dilates blood vessels which reduces the amount of force with which the heart needs to pump blood.

Your veterinarian has prescribed VETMEDIN®-CA1 (pimobendan) because your dog has been diagnosed with myxomatous mitral valve disease (MMVD) at a stage classified as B2 (asymptomatic with a murmur and evidence of significant heart size increase). Although your dog may not have any visible signs of heart disease, VETMEDIN®-CA1 can be used to delay the progression of MMVD to heart failure.

Product sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer.

For
Dogs

Active ingredient(s)
Pimobendan

Inactive ingredients
Complete inactive ingredients list not provided by manufacturer.

Brand name
Vetmedin-CA1

Drug class
Inodilator

Product flavoring
Vetmedin-CA1 Chewable Tablets for Dogs are “beef” flavored.
*Contains pork (does not contain actual beef or chicken)

Manufacturer
Boehringer Ingelheim Animal Health USA

Product strength & size
Vetmedin-CA1 Chewable Tablets may be available in multiple strengths and/or sizes. Please ensure the selected product is appropriate for your pet, as recommended by your veterinarian.
For current availability, please refer to the product selection above.

Usage
*For complete product information, please review the full prescribing information in the manufacturer package insert.

Vetmedin-CA1 Chewable Tablets should be given orally as directed by your veterinarian. Please consult your veterinarian before making any changes or discontinuing the prescribed dosing schedule.
It is important to be consistent with how the medication is given (e.g., timing, with or without food) for every dose.

Manufacturer Dosage and Administration:
VETMEDIN®-CA1 (pimobendan) Chewable Tablets should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets.
The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening).
The tablets are scored, and the calculated dosage should be provided to the nearest half-tablet increment.

Missed doses
Administer the dose as soon as possible. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not give more medication than prescribed or two doses at once.

Storage
Store in a cool, dry place at a controlled room temperature (68 to 77°F, excursions permitted between 59 and 86°F). Keep in a tight, light-resistant container and out of the reach of children and pets. Store away from heat and direct sunlight. Do not store in the bathroom, near the kitchen sink, or in damp places. The medicine may break down if exposed to heat or moisture.

Side effects
The most common side effects seen in dogs with Stage B2 MMVD while taking VETMEDIN-CA1 Chewable Tablets are cough, vomiting, diarrhea, lethargy (lack of energy), and localized pain (such as in the neck or legs).

Contact your veterinarian immediately if your pet has difficulty breathing, collapses or loses consciousness, has a seizure, or appears to be bloated/have increased belly fluid.

Notify your veterinarian if your pet experiences any of the effects described above, or if you notice any other side effects that are persistent or troublesome.
If you notice anything unusual, please consult your veterinarian.

Precautions
*For complete product information including warnings and precautions, please refer to the manufacturer package insert.

For oral use in dogs with diagnosed with Stage B2 myxomatous mitral valve disease (MMVD) only- not for use in humans. Keep this and all medications in a secure location out of reach of children and animals to prevent accidental ingestion or overdose. Consult a physician in case of accidental ingestion by humans.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use VETMEDIN®-CA1 (pimobendan) Chewable Tablets other than as directed in labeling.

Do not administer VETMEDIN®-CA1 (pimobendan) Chewable Tablets in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
Do not administer VETMEDIN-CA1 to dogs with Stage A or B1 preclinical myxomatous mitral valve disease (MMDV) due to the risk of cardiac pathology associated with exaggerated hemodynamic responses to VETMEDIN-CA1.

The safety of VETMEDIN®-CA1 has not been established in dogs with asymptomatic heart disease caused by etiologies other than MMVD. The safe use of VETMEDIN®-CA1 has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, or in breeding, pregnant, or lactating dogs.

Do not administer to animals with a known history or suspected allergy/hypersensitivity to this medication or any of its ingredients. Allergic reactions to medications may occur. Be sure to inform Vetsource and your veterinarian if your pet has any known drug sensitivities or allergies.
If your pet displays symptoms of an allergic reaction, discontinue therapy and call your veterinarian immediately or seek emergency veterinary attention. Symptoms may include (but are not limited to): swollen lips, tongue, face, or airways; difficulty breathing; agitation; profuse salivation; and widespread hives or itching.

Drug and food interactions
The following drugs* may have potential interactions with this medication: beta blockers (e.g., atenolol, sotalol), calcium channel blockers (e.g., amlodipine, diltiazem), and sildenafil.
*NOTE: this may not be a comprehensive list. Contact your veterinarian if your pet experiences any unusual reactions when different medications are given together.

Please ensure your veterinarian is aware of all medications and supplements that your pet is currently receiving. Your veterinarian may prescribe multiple medications, even if a potential drug interaction may occur. In these instances, your veterinarian may adjust the dosages or monitor your pet more closely.

Adverse reactions
If you are concerned that your pet has experienced an adverse reaction to this medication, please contact the manufacturer Boehringer Ingelheim Animal Health USA at 1-888-637-4251 or Vetsource Pet Owner Care at 877-738-4443.

Overdose
If you have any reason to suspect an overdose, call your doctor/veterinarian or the appropriate poison control resource immediately.

For humans:
The national toll-free Poison Help line, 1-800-222-1222, will connect you to your local poison center in case of emergency. This service is available nationwide and in most U.S. territories.

For animals:
The ASPCA Animal Poison Control Center is available 24 hours a day, 365 days a year at 888-426-4435.
Pet Poison Helpline® also provides a 24/7 animal poison control service at 855-764-7661.

*Please note: this information is for third-party services and is provided for convenience in case of potential poison-related emergencies. There may be consultation fee for these services.

Disclaimer
The content provided on this page is NOT medical advice.
All content, including the images and product description above, is intended for general informational purposes only and should not be considered a substitute for professional veterinary consultation, diagnosis, or treatment.
Consult your veterinarian for complete information about this product and how it fits into your pet's individual treatment plan.

Last revised: 8/01/2025
0 Reviews